NRSN icon

NeuroSense Therapeutics
NRSN

Upgrade to unlock
Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
PRNewsWire
15 days ago
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Neutral
PRNewsWire
28 days ago
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Neutral
PRNewsWire
1 month ago
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Neutral
PRNewsWire
2 months ago
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
Neutral
PRNewsWire
2 months ago
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Neutral
PRNewsWire
3 months ago
NeuroSense to Host Investor Webinar on December 8, 2025
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Host Investor Webinar on December 8, 2025
Neutral
PRNewsWire
4 months ago
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
Neutral
PRNewsWire
4 months ago
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Neutral
PRNewsWire
5 months ago
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass. , Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Neutral
PRNewsWire
6 months ago
NeuroSense Provides Business Update and Progress for the First Half of 2025
CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Provides Business Update and Progress for the First Half of 2025
See News Rankings